Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy Ruchika Sharma3 April 2025 4:30 PM ISTEast Hanover: Novartis has received accelerated approval from the US Food and Drug Administration (FDA) for Vanrafia...
Novartis oral Fabhalta secures USFDA okay for adults with C3 glomerulopathy Ruchika Sharma21 March 2025 12:42 PM ISTBasel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has approved oral Fabhalta (iptacopan) for the treatment...
Proteinuria Linked to Increased Risk of Atrial Fibrillation Across All Glycemic Stages: Study Finds Medha Baranwal3 Feb 2025 8:00 AM ISTSouth Korea: A recent nationwide population-based cohort study has shed light on the significant relationship between proteinuria and the risk of...
Study Highlights Risk of Proteinuria in Patients Receiving Immune Checkpoint Inhibitors Medha Baranwal27 Jan 2025 8:30 PM ISTChina: A recent case-control observational study has raised concerns about developing proteinuria in patients undergoing immune checkpoint inhibitors...
Study Shows Variable Response to Spironolactone in IgA Nephropathy; Safety Confirmed in Higher eGFR Patients Medha Baranwal16 Sept 2024 4:30 AM ISTChina: A recent study published in Kidney and Blood Pressure Research has validated that spironolactone effectively reduces urine protein excretion in...
Superior Renal Protection: Tocilizumab Emerges as Leader in AA amyloidosis Treatment, study finds Medha Baranwal6 Sept 2024 8:30 AM ISTGermany: A recent study has shown the superior efficacy of tocilizumab compared to other bDMARDs in managing systemic inflammation in patients with...
Proteinuria clinically useful predictive marker for developing ocular motor cranial nerve palsy : Study Dr Riya Dave23 Aug 2024 8:00 AM ISTLarge-scale population study researchers have observed a significant association of proteinuria detected by dipstick with the incidence of oculomotor...
Low-Dose Spironolactone found Effective for Proteinuria Reduction in IgA Nephropathy, suggests study Dr. Shravani Dali8 Aug 2024 8:30 PM ISTLow-dose spironolactone found Effective for Proteinuria Reduction in IgA Nephropathy, suggests a study published in the Kidney Blood Press.It's...
Novartis bags USFDA accelerated approval for Fabhalta for reduction of proteinuria in primary IgA nephropathy Ruchika Sharma8 Aug 2024 11:30 AM ISTBasel: Novartis has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Fabhalta (iptacopan), a...
Iptacopan significantly reduce proteinuria in patients with C3 glomerulopathy, reveals APPEAR-C3G trial Dr. Kamal Kant Kohli1 Jun 2024 7:30 AM ISTNovartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta (iptacopan) at the late-breaking...
Nephrosclerosis patients without diabetes and low levels of proteinuria may have rapid kidney function decline: Study Medha Baranwal29 May 2024 10:00 AM ISTJapan: A groundbreaking post hoc analysis of the BRIGHTEN study has shed light on the intricate relationship between proteinuria and rapid kidney...
Sparsentan superior to irbesartan in focal segmental glomerulosclerosis patients, reveals DUPLEX trial Dr Kartikeya Kohli22 May 2024 8:30 AM ISTUSA: A groundbreaking clinical trial, known as the DUPLEX trial, has unveiled promising results in treating Focal Segmental Glomerulosclerosis (FSGS),...
